Ovarian cancer and hormone replacement therapy in the Million Women Study

Lancet

Volumn 369, Issue 9574, 2007, Pages 1703-1710

  Beral, Valerie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER MORTALITY; CLEAR CELL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INCIDENCE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARIECTOMY; OVARY CANCER; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SOCIOECONOMICS; TREATMENT DURATION; UNITED KINGDOM;

EID: 34248574353     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60534-0     Document Type: Article

References (30)

1. International Agency for Research on Cancer. http://www-dep.iarc.fr (accessed April 3, 2007).
2. National Statistics. http://www.statistics.gov.uk/onlineproducts/#health (accessed April 3, 2007).
3. Weiss N., Lyon J., Krishnamurthy S., Dietert S., Liff J., and Daling J. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68 (1982) 95-98
4. La Vecchia C., Liberati A., and Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 69 (1982) 1207
5. Hartge P., Hoover R., McGowan L., Lesher L., and Norris H. Menopause and ovarian cancer. Am J Epidemiol 127 (1988) 990-998
6. Kaufmann D., Kelly J., Welch W., et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 130 (1989) 1142-1151
7. Risch H. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol J 63 (1996) 254-257
8. Risch H., Marrett L., Jain M., and Howe G. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144 (1996) 363-372
9. Hempling R., Wong C., Piver M., Natarajan N., and Mettlin C. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89 (1997) 1012-1016
10. Purdie D., Bain C., Siskind V., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Brit Cancer 81 (1999) 559-563
11. Rodriguez C., Patel A., Calle E., Jacob E., and Thun M. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (2001) 1460-1465
12. Bosetti C., Negri E., Franceschi S., Trichopoulos D., Beral V., and La Vecchia C. Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285 (2001) 308
13. Riman T., Dickman P., Nilsson s., et al. Hormone replacement therapy and risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94 (2002) 497-504
14. Lacey J., Mink P., Lubin J., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (2002) 334-341
15. Anderson G., Judd H., Kaunitz, et al. Effect of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA 290 (2003) 1739-1744
16. Bakken K., Alsaker E., Eggen A., and Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 112 (2004) 130-134
17. Folsom A., Anderson J., and Ross J. Estrogen replacement therapy and ovarian cancer. Epidemiology 15 (2004) 100-104
18. Glud E., Kjaer S., Thomsen B., et al. Hormone replace-ment therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164 (2004) 2253-2259
19. Pike M., Pearce C., Peters R., Cozen W., Wan P., and Wu A. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82 (2004) 186-195
20. Lacey J., Brinton L., Leitzmann M., et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98 (2006) 1397-1405
21. Million Women Study Collaborative Group. The Million Women Study: design and characteristics of the study population. Breast Cancer Research 1 (1999) 73-80
22. World Health Organisation. International Classification of Diseases. 10th Edition (1994), World Health Organisation, Geneva
23. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
24. Million Women Study Collaborators. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
25. Lunn M., and McNeil D. Applying Cox regression to competing risks. Biometrics 51 (1995) 524-532
26. Reeves G., Beral V., Green J., Gathani T., Bull D., and for the Million Women Study Collaborators. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 11 (2006) 910-918
27. Banks E., Beral V., Cameron R., et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostatistics 6 (2001) 357-363
28. Beral V., Banks E., Reeves G., and Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostatistics 4 (1999) 191-215
29. IARC monographs on the evaluation of carcinogenic risks to humans. Hormonal contraception and post-menopausal hormonal therapy Vol 72 (1999), IARC Press, Lyon
30. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350 (1997) 1047-1059